Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer

BACKGROUND: A small proportion of patients with non-small cell lung cancer (NSCLC) experience objective clinical benefit after neoadjuvant programmed cell death 1 (PD-1) blockade. A neoadjuvant therapeutic regimen combining immune checkpoint blockade with chemotherapy might improve the treatment eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yulong, Yan, Bo, Xu, Feng, Hui, Zhenzhen, Zhao, Gang, Liu, Jie, Zhang, Huan, Zeng, Ziqing, Zhang, Ran, Provencio, Mariano, Ren, Xiubao, You, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182703/
https://www.ncbi.nlm.nih.gov/pubmed/34164269
http://dx.doi.org/10.21037/tlcr-21-329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182703/
https://www.ncbi.nlm.nih.gov/pubmed/34164269
http://dx.doi.org/10.21037/tlcr-21-329

Ejemplares similares